Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2026.1815252 Correction Correction: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the Serpinc1 gene ZhangJun 1 Investigation Conceptualization Software Resources Writing – original draft Validation Project administration Visualization Methodology Formal analysis Data curation TangZhijia 1 Writing – review & editing Validation Visualization Formal analysis GuoXi 2 Writing – review & editing Investigation Conceptualization Methodology WangYunxia 1 Investigation Methodology Data curation Writing – review & editing Conceptualization Formal analysis ZhouYuhong 2 Supervision Writing – review & editing Conceptualization CaiWeimin 1 * Validation Supervision Conceptualization Funding acquisition Writing – review & editing Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China Correspondence: Weimin Cai, weimincai@fudan.edu.cn 03 03 2026 2026 16 1815252 22 02 2026 24 02 2026 Copyright © 2026 Zhang, Tang, Guo, Wang, Zhou and Cai. 2026 Zhang, Tang, Guo, Wang, Zhou and Cai https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene By Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2022) Front. Oncol. 12:933646. doi: 10.3389/fonc.2022.933646 albumin-bound paclitaxel combination drug therapy lung cancer PD-1 Serpinc1 National Natural Science Foundation of China 10.13039/501100001809 section-at-acceptance Molecular and Cellular Oncology

In the published article, there was an error in the Funding statement. The funding number was incorrectly written as “8217130423” rather than “82173892”. The correct Funding statement appears below.

“This work was supported by grant from the National Natural Science Foundation of China [Grant No. 82173892].”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland